AN ANTIBODY FOR MACROPHAGE MIGRATION INHIBITORY FACTOR SUPPRESSES TUMOUR GROWTH AND INHIBITS TUMOUR-ASSOCIATED ANGIOGENESIS

To verify the role of macrophage migration inhibitory factor (MIF) in tumourigenesis, we examined the effect of an anti-MIF antibody on tumour growth and angiogenesis. We inoculated murine colon adenocarcinoma cell line colon 26 cells subcutaneously into the flank in BALB/c mice. After nine days, we...

Full description

Saved in:
Bibliographic Details
Published in:Cytokine (Philadelphia, Pa.) Pa.), 2000-04, Vol.12 (4), p.309-314
Main Authors: Ogawa, Hideaki, Nishihira, Jun, Sato, Yuji, Kondo, Masao, Takahashi, Norihiko, Oshima, Takahiro, Todo, Satoru
Format: Article
Language:English
Subjects:
Adenocarcinoma - immunology
Adenocarcinoma - physiopathology
angiogenesis/antibody/colorectal adenocarcinoma/macrophage migration inhibitory factor/vascular endothelial cells
Animals
Antibodies, Monoclonal - immunology
Cells, Cultured
Colonic Neoplasms - immunology
Colonic Neoplasms - physiopathology
Endothelium, Vascular - cytology
Female
Humans
Macrophage Migration-Inhibitory Factors - immunology
Mice
Mice, Inbred BALB C
Neoplasm Transplantation
Neovascularization, Pathologic - immunology
Rats
Thymidine - metabolism
Tritium - metabolism
Tumor Cells, Cultured
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To verify the role of macrophage migration inhibitory factor (MIF) in tumourigenesis, we examined the effect of an anti-MIF antibody on tumour growth and angiogenesis. We inoculated murine colon adenocarcinoma cell line colon 26 cells subcutaneously into the flank in BALB/c mice. After nine days, we treated tumour-bearing mice with an anti-rat MIF antibody by intraperitoneal injection on days 9, 11, 13, 15, 17, 19 and 21. We found significant inhibition of tumour growth by this treatment from day 15 to day 22. Next, we implanted a chamber filled with colon 26 cells, which only passes soluble factors, in the subcutaneous fascia of the flank, and treated mice with the anti-rat MIF antibody at days 1, 3 and 5. By histological examination at day 6, angiogenesis within the subcutaneous fascia in contact with the chamber was markedly suppressed. In vitro, we added an anti-human MIF antibody to human umbilical vein endothelial cells (HUVEC) to evaluate its effect on cell growth by measurement of [3H]thymidine incorporation. We observed that the anti-MIF antibody significantly suppressed [3H]thymidine uptake by HUVEC. These results suggest the possibility that MIF is involved in tumourigenesis via promotion of angiogenesis.
ISSN:1043-4666
1096-0023
DOI:10.1006/cyto.1999.0562